Market Research Logo

MagForce AG (MF6) - Product Pipeline Analysis, 2018 Update

Summary

MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. MagForce’s NanoTherm is a liquid that reacts to the presence of magnetic field. The company’s NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. Its products are used in the treatment of prostate cancer, pancreatic cancer, esophageal cancer and glioblastoma. The company operates through therapy centers located in Berlin, Munster, Kiel, Cologne and Frankfurt, Germany. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company MagForce AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


MagForce AG Company Overview
MagForce AG Company Snapshot
MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
MagForce AG – Pipeline Analysis Overview
MagForce AG - Key Facts
MagForce AG - Major Products and Services
MagForce AG Pipeline Products by Development Stage
MagForce AG Ongoing Clinical Trials by Trial Status
MagForce AG Pipeline Products Overview
NanoTherm - Brain Cancer
NanoTherm - Brain Cancer Product Overview
NanoTherm - Gastrointestinal Cancer
NanoTherm - Gastrointestinal Cancer Product Overview
NanoTherm - Pancreatic Carcinoma
NanoTherm - Pancreatic Carcinoma Product Overview
NanoTherm - Prostate Carcinoma
NanoTherm - Prostate Carcinoma Product Overview
NanoTherm - Prostate Carcinoma Clinical Trial
NanoTherm - Recurrent Glioblastoma
NanoTherm - Recurrent Glioblastoma Product Overview
Next-Generation Nanotherm
Next-Generation Nanotherm Product Overview
MagForce AG - Key Competitors
MagForce AG - Key Employees
MagForce AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
MagForce AG, Recent Developments
Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy
Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster’s Annual Brain Cancer Patient Event
Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland
Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)
May 03, 2018: MagForce Publishes Financial Results for the Year 2017 and Operative Highlights
Feb 15, 2018: FDA expands treatment window for use of clot retrieval devices in certain stroke patients
Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer
Nov 14, 2017: MagForce to participate at SNO 2017 Annual Meeting from November 16-19 in San Francisco, USA
Sep 29, 2017: MagForce Publishes Financial Results for the First Half of 2017 and Operative Highlights
Aug 10, 2017: MagForce announces positive results of 2017 Annual General Meeting
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
MagForce AG Pipeline Products by Equipment Type
MagForce AG Pipeline Products by Indication
MagForce AG Ongoing Clinical Trials by Trial Status
MagForce AG, Key Facts
MagForce AG, Major Products and Services
MagForce AG Number of Pipeline Products by Development Stage
MagForce AG Pipeline Products Summary by Development Stage
MagForce AG Ongoing Clinical Trials by Trial Status
MagForce AG Ongoing Clinical Trials Summary
NanoTherm - Brain Cancer - Product Status
NanoTherm - Brain Cancer - Product Description
NanoTherm - Gastrointestinal Cancer - Product Status
NanoTherm - Gastrointestinal Cancer - Product Description
NanoTherm - Pancreatic Carcinoma - Product Status
NanoTherm - Pancreatic Carcinoma - Product Description
NanoTherm - Prostate Carcinoma - Product Status
NanoTherm - Prostate Carcinoma - Product Description
NanoTherm - Prostate Carcinoma - An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer
NanoTherm - Recurrent Glioblastoma - Product Status
NanoTherm - Recurrent Glioblastoma - Product Description
Next-Generation Nanotherm - Product Status
Next-Generation Nanotherm - Product Description
MagForce AG, Key Employees
MagForce AG, Other Locations
MagForce AG, Subsidiaries
Glossary
List of Figures
MagForce AG Pipeline Products by Equipment Type
MagForce AG Pipeline Products by Development Stage
MagForce AG Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report